These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 1382552)
1. The optimisation of carboplatin dose in carboplatin, etoposide and bleomycin combination chemotherapy for good prognosis metastatic nonseminomatous germ cell tumours of the testis. Childs WJ; Nicholls EJ; Horwich A Ann Oncol; 1992 Apr; 3(4):291-6. PubMed ID: 1382552 [TBL] [Abstract][Full Text] [Related]
2. Effectiveness of carboplatin, etoposide, and bleomycin combination chemotherapy in good-prognosis metastatic testicular nonseminomatous germ cell tumors. Horwich A; Dearnaley DP; Nicholls J; Jay G; Mason M; Harland S; Peckham MJ; Hendry WF J Clin Oncol; 1991 Jan; 9(1):62-9. PubMed ID: 1702147 [TBL] [Abstract][Full Text] [Related]
3. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. Horwich A; Sleijfer DT; Fosså SD; Kaye SB; Oliver RT; Cullen MH; Mead GM; de Wit R; de Mulder PH; Dearnaley DP; Cook PA; Sylvester RJ; Stenning SP J Clin Oncol; 1997 May; 15(5):1844-52. PubMed ID: 9164194 [TBL] [Abstract][Full Text] [Related]
4. A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with 'good-risk' metastatic non-seminomatous germ cell tumors. Bokemeyer C; Köhrmann O; Tischler J; Weissbach L; Räth U; Haupt A; Schöffski P; Harstrick A; Schmoll HJ Ann Oncol; 1996 Dec; 7(10):1015-21. PubMed ID: 9037359 [TBL] [Abstract][Full Text] [Related]
5. Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma. Newell DR; Eeles RA; Gumbrell LA; Boxall FE; Horwich A; Calvert AH Cancer Chemother Pharmacol; 1989; 23(6):367-72. PubMed ID: 2469544 [TBL] [Abstract][Full Text] [Related]
6. [Carboplatin-etoposide-bleomycine chemotherapy protocol in the treatment of patients with metastatic non-seminomatous germ-cell testicular tumours with good prognosis]. Jeremić B; Djurić Lj; Djordjević S; Cirović V; Milojević Lj; Stanisavljević B; Matović M; Mijatović Lj Srp Arh Celok Lek; 1994; 122(9-10):257-9. PubMed ID: 17977429 [TBL] [Abstract][Full Text] [Related]
7. Carboplatin dose in combination chemotherapy for testicular cancer. Harland SJ; Gumbrell LA; Horwich A Eur J Cancer; 1991; 27(6):691-5. PubMed ID: 1712607 [TBL] [Abstract][Full Text] [Related]
9. Risk-adapted treatment for patients with clinical stage I nonseminomatous germ cell tumor of the testis. Amato RJ; Ro JY; Ayala AG; Swanson DA Urology; 2004 Jan; 63(1):144-8; discussion 148-9. PubMed ID: 14751368 [TBL] [Abstract][Full Text] [Related]
10. Risk-adapted chemotherapy of germ cell tumors with carboplatin, etoposide and bleomycin for low-risk and cisplatin, etoposide and ifosfamide for high-risk patients. A single-center study. Tscherry G; Jacky E; Jost LM; Stahel RA Oncology; 2000 Aug; 59(2):110-7. PubMed ID: 10971168 [TBL] [Abstract][Full Text] [Related]
11. Treatment of favorable-prognosis nonseminomatous testicular germ cell tumors with etoposide, cisplatin, and reduced dose of bleomycin. Brada M; Horwich A; Peckham MJ Cancer Treat Rep; 1987 Jun; 71(6):655-6. PubMed ID: 2438041 [TBL] [Abstract][Full Text] [Related]
12. Use of carboplatin in germ cell tumors of the testis. Horwich A; Mason M; Dearnaley DP Semin Oncol; 1992 Feb; 19(1 Suppl 2):72-7. PubMed ID: 1329224 [TBL] [Abstract][Full Text] [Related]
13. Sequential trials of cisplatin, vinblastine, and bleomycin and etoposide and cisplatin in disseminated nonseminomatous germ cell tumors of the testis with a good prognosis at a single institution. Germá JR; Sagarra AF; Izquierdo MA; Seguí MA Cancer; 1993 Feb; 71(3):796-803. PubMed ID: 7679314 [TBL] [Abstract][Full Text] [Related]
14. Phase I/II trial of carboplatin dose escalation in combination chemotherapy with etoposide, bleomycin and GM-CSF support for poor prognosis nonseminomatous germ cell tumors patients. Tjulandin SA; Stenina MB; Sidorova NJ; Delgado FG; Sokolov AV; Molchanov GV; Ljubimova NV; Garin AM Neoplasma; 1996; 43(5):347-52. PubMed ID: 8996556 [TBL] [Abstract][Full Text] [Related]
15. Treating stage I nonseminomatous germ cell tumours with a single cycle of chemotherapy. Gilbert DC; Norman AR; Nicholl J; Dearnaley DP; Horwich A; Huddart RA BJU Int; 2006 Jul; 98(1):67-9. PubMed ID: 16831145 [TBL] [Abstract][Full Text] [Related]
16. Two cycles of carboplatin-based adjuvant chemotherapy for high-risk clinical stage I and stage IM non-seminomatous germ cell tumours of the testis: a HECOG trial. Pectasides D; Skarlos D; Dimopoulos AM; Farmakis D; Pectasides M; Fountzilas G; Aravantinos G Anticancer Res; 2003; 23(5b):4239-44. PubMed ID: 14666633 [TBL] [Abstract][Full Text] [Related]
17. Does the number of cycles of cisplatin based chemotherapy have any effect on renal function in patients with testicular germ cell tumor? Suer E; Mermerkaya M; Gülpınar Ö; Afandiyev F; Baltacı S; Türkölmez K; Bedük Y J Urol; 2013 Dec; 190(6):2081-5. PubMed ID: 23764076 [TBL] [Abstract][Full Text] [Related]
18. High failure rate of carboplatin-etoposide combination in good risk non-seminomatous germ cell tumours. Kattan J; Mahjoubi M; Droz JP; Kramar A; Culine S; Boutan-Laroze A; Chazard M Eur J Cancer; 1993; 29A(11):1504-9. PubMed ID: 8217352 [TBL] [Abstract][Full Text] [Related]
19. [Testicular malignant tumours. Efficacy of germ cell and sex cord tumours treatment protocol in Poland]. Popadiuk S; Korzon M; Chybicka A; Szmyd K; Dzierzega M; Trelińska J; Kowalczyk JR; Wiśniewska-Slusarz H; Woźniak W; Bilska K; Wachowiak J; Konatkowska B; Wysocki M; Krawczuk-Rybak M; Czauderna P; Szumera M; Sznurkowska K; Renke J Med Wieku Rozwoj; 2006; 10(3 Pt 1):811-7. PubMed ID: 17317912 [TBL] [Abstract][Full Text] [Related]
20. Paclitaxel+BEP (T-BEP) regimen as induction chemotherapy in poor prognosis patients with nonseminomatous germ cell tumors: a phase II study. Tryakin A; Fedyanin M; Kanagavel D; Fainstein I; Sergeev J; Polockij B; Matveev V; Zakharova T; Garin A; Tjulandin S Urology; 2011 Sep; 78(3):620-5. PubMed ID: 21764427 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]